These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 36026595)
1. Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis. Qi J; Nguyen NC Clin Nucl Med; 2022 Dec; 47(12):1061-1062. PubMed ID: 36026595 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for Kim EH; Siegel BA; Teoh EJ; Andriole GL; Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848 [TBL] [Abstract][Full Text] [Related]
4. Negative 18 F-Piflufolastat PET/CT, But Positive 18 F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer. Ulaner GA Clin Nucl Med; 2024 Oct; 49(10):968-970. PubMed ID: 38693630 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Chen B; Wei P; Macapinlac HA; Lu Y Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613 [TBL] [Abstract][Full Text] [Related]
6. Detection of Adenocarcinoma of the Colon on 18 F-Fluciclovine PET/CT. Desai C; Clark A; Surasi DS; Flynt L Clin Nucl Med; 2024 Jun; 49(6):543-545. PubMed ID: 38598733 [TBL] [Abstract][Full Text] [Related]